Search Results - "Bolinger, Andrew A"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
  2. 2

    Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023 by Ali, Saghir, Bolinger, Andrew A, Zhou, Jia

    Published in Current topics in medicinal chemistry (01-01-2024)
    “…Fluorine continues to show its potential applications in drug discovery and development, as reflected by twelve drugs being fluorinated out of the fifty-five…”
    Get more information
    Journal Article
  3. 3

    RIPTACs: A groundbreaking approach to drug discovery by Ma, Zonghui, Bolinger, Andrew A., Zhou, Jia

    Published in Drug discovery today (01-11-2023)
    “…•A groundbreaking drug discovery approach using regulated induced proximity targeting chimeras (RIPTACs) is introduced.•Proof-of-concept and preliminary…”
    Get full text
    Journal Article
  4. 4

    Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2) by Ma, Zonghui, Bolinger, Andrew A., Chen, Haiying, Zhou, Jia

    Published in Journal of medicinal chemistry (24-08-2023)
    “…Nuclear receptor binding SET domain proteins (NSDs) catalyze the mono- or dimethylation of histone 3 lysine 36 (H3K36me1 and H3K36me2), using…”
    Get full text
    Journal Article
  5. 5

    Novel approaches to targeted protein degradation technologies in drug discovery by Xue, Yu, Bolinger, Andrew A, Zhou, Jia

    Published in Expert opinion on drug discovery (03-04-2023)
    “…Target protein degradation (TPD) provides a novel therapeutic modality, other than inhibition, through the direct depletion of target proteins. Two primary…”
    Get more information
    Journal Article
  6. 6

    Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics by Ma, Zonghui, Bolinger, Andrew A, Zhou, Jia, Tian, Bing

    “…Inflammatory bowel diseases (IBDs) are debilitating chronic inflammatory disorders with increasing prevalence worldwide. Epigenetic regulator…”
    Get more information
    Journal Article
  7. 7

    Therapeutic potential of salicylamide derivatives for combating viral infections by Xu, Jimin, Xue, Yu, Bolinger, Andrew A., Li, Jun, Zhou, Mingxiang, Chen, Haiying, Li, Hongmin, Zhou, Jia

    Published in Medicinal research reviews (01-07-2023)
    “…Since time immemorial human beings have constantly been fighting against viral infections. The ongoing and devastating coronavirus disease 2019 pandemic…”
    Get full text
    Journal Article
  8. 8

    Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases by Li, Yi, Chen, Jianping, Bolinger, Andrew A, Chen, Haiying, Liu, Zhiqing, Cong, Yingzi, Brasier, Allan R, Pinchuk, Irina V, Tian, Bing, Zhou, Jia

    Published in Inflammatory bowel diseases (15-11-2021)
    “…Abstract Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a class of severe and chronic diseases of the…”
    Get full text
    Journal Article
  9. 9

    Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators by Xu, Jimin, Shi, Shuizhen, Liu, Gang, Xie, Xuping, Li, Jun, Bolinger, Andrew A., Chen, Haiying, Zhang, Wenbo, Shi, Pei-Yong, Liu, Hua, Zhou, Jia

    Published in European journal of medicinal chemistry (15-01-2023)
    “…Sirt6 activation has emerged as a promising drug target for the treatment of various human diseases, while only limited Sirt6 activators have been reported…”
    Get full text
    Journal Article
  10. 10

    Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target by Bolinger, Andrew A., Frazier, Andrew, La, Jun-Ho, Allen, John A., Zhou, Jia

    Published in ACS chemical neuroscience (20-09-2023)
    “…G protein-coupled receptors (GPCRs) are successful druggable targets, making up around 35% of all FDA-approved medications. However, a large number of…”
    Get full text
    Journal Article
  11. 11
  12. 12